MUSTAFA MOAZAM: Open Payments
NPI 1306987474 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,050 in 38 payments from 16 companies in 2025. Trend: 2023 $527 · 2024 $624 · 2025 $1,050
Food & beverage: $1,050
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $215 |
| Otsuka America Pharmaceutical, Inc. | 6 | $164 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $163 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $81 |
| Abbott Laboratories | 1 | $76 |
| ABBVIE INC. | 5 | $75 |
| GENZYME CORPORATION | 2 | $62 |
| Novo Nordisk Inc | 2 | $44 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Exact Sciences Corporation | 1 | $26 |
Products named: ABILIFY MAINTENA, BREZTRI, Jivi, FARXIGA, CAPLYTA, FREESTYLE LIBRE 3, VRAYLAR, Kerendia.
Industry payments across TX — which companies pay providers there.
